Allogene Therapeutics (ALLO) Expected to Announce Earnings on Thursday

Allogene Therapeutics (NASDAQ:ALLO) will likely be announcing its Q4 2025 results after the market closes on Thursday, March 12th. Analysts expect the company to announce earnings of ($0.25) per share and revenue of $0.0020 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 12, 2026 at 5:00 PM ET.

Allogene Therapeutics Price Performance

NASDAQ:ALLO opened at $2.53 on Thursday. The business’s 50-day moving average price is $1.78 and its 200 day moving average price is $1.44. Allogene Therapeutics has a 52-week low of $0.86 and a 52-week high of $2.80. The firm has a market cap of $568.57 million, a P/E ratio of -2.58 and a beta of 0.50.

Insider Activity

In related news, SVP Earl Martin Douglas sold 22,900 shares of the stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $1.76, for a total value of $40,304.00. Following the completion of the sale, the senior vice president directly owned 564,948 shares of the company’s stock, valued at approximately $994,308.48. This represents a 3.90% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Geoffrey M. Parker sold 24,001 shares of the firm’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $1.76, for a total value of $42,241.76. Following the sale, the chief financial officer owned 1,252,795 shares of the company’s stock, valued at $2,204,919.20. The trade was a 1.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 222,987 shares of company stock valued at $396,969 in the last 90 days. Company insiders own 13.20% of the company’s stock.

Hedge Funds Weigh In On Allogene Therapeutics

Large investors have recently made changes to their positions in the business. Russell Investments Group Ltd. boosted its holdings in shares of Allogene Therapeutics by 11,159.8% during the third quarter. Russell Investments Group Ltd. now owns 21,844 shares of the company’s stock worth $27,000 after purchasing an additional 21,650 shares during the period. Mercer Global Advisors Inc. ADV acquired a new position in Allogene Therapeutics in the 3rd quarter valued at approximately $30,000. Caitong International Asset Management Co. Ltd lifted its position in Allogene Therapeutics by 5,267.6% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 24,047 shares of the company’s stock worth $30,000 after buying an additional 23,599 shares in the last quarter. Scientech Research LLC acquired a new stake in shares of Allogene Therapeutics during the 3rd quarter valued at $33,000. Finally, CANADA LIFE ASSURANCE Co boosted its stake in shares of Allogene Therapeutics by 142.0% during the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 31,211 shares of the company’s stock valued at $35,000 after buying an additional 18,314 shares during the period. Institutional investors and hedge funds own 83.63% of the company’s stock.

Analysts Set New Price Targets

ALLO has been the topic of several recent research reports. Citizens Jmp raised shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price objective on the stock in a research note on Friday, January 9th. Citigroup raised Allogene Therapeutics from a “market perform” rating to an “outperform” rating in a report on Friday, January 9th. UBS Group began coverage on Allogene Therapeutics in a research note on Wednesday, January 7th. They set a “buy” rating and a $8.00 price objective for the company. Finally, Wall Street Zen upgraded Allogene Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, February 22nd. Ten research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $8.40.

About Allogene Therapeutics

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.